Follow The Filings

NXTC NextCure

NextCure earnings company data as of 4:45 AM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS -0.90 — —
Rev — — —

Insider trades

Open-market buys and sales by NXTC's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NXTC insider trades
  • $1.8M bought by 1 insider
  • $185K sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. ADAR1 Capital Management, LLC 10% owner, +1 joint filer
    Buy
    $54K 10,851 shares at $4.95 +1.5% to stake
    Traded Oct 23–27 Filed Oct 27
  2. Simcere Zaiming, Inc. Insider, +5 joint filers
    Sale
    $185K 30,000 shares at $6.16 8.9% of stake
    Traded Aug 10 Filed Aug 12
  3. ADAR1 Capital Management, LLC 10% owner, +1 joint filer
    Buy
    $1.6M 329,153 shares at $4.93 +84% to stake
    Traded Jul 30–31 Filed Aug 3
  4. ADAR1 Capital Management, LLC 10% owner, +1 joint filer
    Buy
    $88K 17,608 shares at $4.98 +4.7% to stake
    Traded Jul 27–29 Filed Jul 29

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 5.02
SCHEDULE 13G —
8-K 8.01,9.01
8-K 1.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G —
8-K 2.02,9.01
10-Q
8-K 1.01,2.05,5.01,5.02,7.01,8.01,9.01
8-K 5.02,5.07,9.01
8-K 7.01,8.01,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
DEF 14A FORM DEF 14A
DEFA14A
SCHEDULE 13D/A —
8-K 2.02,9.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13G —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.